Ibalizumab in Multidrug-Resistant HIV — Accepting Uncertainty

The Food and Drug Administration (FDA) has long recognized that physicians and patients are generally willing to accept greater risks from drugs used to treat life-threatening illnesses than they would from drugs used for less serious illnesses. The agency has therefore exercised broad flexibility…

Read the full post on The New England Journal of Medicine: Search Results in Health Policy and Reform